Two decades of vaccine development against atherosclerosis
Source abstract
Abstract
Atherosclerosis is an immune-mediated chronic inflammatory disease that leads to the development of fatty plaques in the arterial walls, ultimately increasing the risk of thrombosis, stroke, and myocardial infarction. The immune response in this complex disease is both atheroprotective and pro-atherogenic, involving both innate and adaptive immunity. Current treatments include the adjustment of lifestyle factors, cholesterol-lowering drugs such as statins, and immunotherapy, whereas vaccine development has received comparatively little attention. In this review, we discuss the potential of antigen-specific vaccination as a preventative approach based on more than 20 years of research and innovation. Vaccination targets include proteins that are more abundant in atherosclerotic patients, such as oxidized low-density lipoprotein (LDL), apolipoprotein B-100, proprotein convertase subtilisin/kexin type-9 serine protease (PCSK9), cholesteryl ester transfer protein (CETP), and heat shock proteins HSP60 and HSP65. Immunization with such proteins or their peptide epitopes has been shown to induce T-cell activation, produce antigen-specific antibodies, reduce the size of atherosclerotic lesions, and/or reduce serum cholesterol levels. Vaccination against atherosclerosis therefore offers a new strategy to address the burden on healthcare systems caused by cardiovascular disease, the leading cause of death worldwide.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Atherosclerosis and Cardiovascular Diseases · Systemic Lupus Erythematosus Research · Inflammasome and immune disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cardiovascular diseases (CVDs). 〈https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)〉.
2. The immunology of atherosclerosis10.1038/nrneph.2017.51 ↗
3. Atherosclerosis stabilization with PCSK-9 inhibition: an evolving concept for cardiovascular prevention10.1016/j.atherosclerosis.2015.10.023 ↗
4. The why and how of adaptive immune responses in ischemic cardiovascular disease10.1038/s44161-022-00049-1 ↗
5. Immunity and inflammation in atherosclerosis10.1161/CIRCRESAHA.118.313591 ↗
6. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials10.1016/j.jacc.2014.02.615 ↗
7. Antiinflammatory therapy with canakinumab for atherosclerotic disease10.1056/NEJMoa1707914 ↗
8. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis10.1038/nature00804 ↗
9. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima10.1046/j.1365-2796.2000.00655.x ↗
10. The immune system in atherosclerosis10.1038/ni.2001 ↗
11. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis - PubMed. 〈https://pubmed.ncbi.nlm.nih.gov/1990440/〉.
12. Local proliferation dominates lesional macrophage accumulation in atherosclerosis10.1038/nm.3258 ↗
13. Macrophages in atherosclerosis: a dynamic balance10.1038/nri3520 ↗
14. CD36 modulates migration of mouse and human macrophages in response to oxidized LDL and may contribute to macrophage trapping in the arterial intima
15. Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis10.1172/JCI111934 ↗
16. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques10.1073/pnas.0403259101 ↗
17. Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis10.1016/S0002-8703(96)90268-9 ↗
18. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein10.1073/pnas.92.9.3893 ↗
19. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque10.1161/01.ATV.6.2.131 ↗
20. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis10.1161/ATVBAHA.109.202671 ↗
21. High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction10.1093/eurheartj/ehn336 ↗
22. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice10.1038/s41586-018-0198-8 ↗
23. FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity10.1016/j.jcmg.2014.06.021 ↗
24. Evolocumab and clinical outcomes in patients with cardiovascular disease10.1056/NEJMoa1615664 ↗
25. Alirocumab and cardiovascular outcomes after acute coronary syndrome10.1056/NEJMoa1801174 ↗
26. Amgen. 2-part, Phase 2/3 Study to Assess the Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part A - Open-label, Single-arm, Multicenter Pilot Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. Part B - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 in Subjects With Homozygous Familial Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT01588496〉 (2018).
27. Amgen. A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial. 〈https://clinicaltrials.gov/ct2/show/NCT02207634〉 (2017).
28. Amgen. A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor. https://clinicaltrials.gov/ct2/show/NCT01763905 (2020).
29. Amgen. A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Japanese Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects. 〈https://clinicaltrials.gov/ct2/show/NCT02634580〉 (2020).
30. Amgen. A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects. https://clinicaltrials.gov/ct2/show/NCT01984424 (2018).
31. Amgen. A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization. https://clinicaltrials.gov/ct2/show/NCT01813422 (2019).
32. Amgen. A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia. 〈https://clinicaltrials.gov/ct2/show/NCT01763866〉 (2021).
33. Amgen. A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less. https://clinicaltrials.gov/ct2/show/NCT01763827 (2020).
34. Amgen. A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease. https://clinicaltrials.gov/ct2/show/NCT01764633 (2019).
35. Amgen. A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects. 〈https://clinicaltrials.gov/ct2/show/NCT01516879〉 (2018).
36. Amgen. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia (BERSON). 〈https://clinicaltrials.gov/ct2/show/NCT02662569〉 (2019).
37. Amgen. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia. https://clinicaltrials.gov/ct2/show/NCT01763918 (2019).
38. Amgen. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia. 〈https://clinicaltrials.gov/ct2/show/NCT01953328〉 (2015).
39. Amgen. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial Hypercholesterolemia. https://clinicaltrials.gov/ct2/show/NCT01375751 (2021).
40. Amgen. A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab). https://clinicaltrials.gov/ct2/show/NCT01439880 (2019).
41. Amgen. A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145. https://clinicaltrials.gov/ct2/show/NCT01854918 (2019).
42. Amgen. A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT01624142〉 (2019).
43. Amgen. A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW). 〈https://clinicaltrials.gov/ct2/show/NCT02729025〉 (2019).
44. Amgen. A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment. 〈https://clinicaltrials.gov/ct2/show/NCT02585895〉 (2017).
45. Amgen. A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment. https://clinicaltrials.gov/ct2/show/NCT02585895 (2017).
46. Amgen. A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor. 〈https://clinicaltrials.gov/ct2/show/NCT01375764〉 (2021).
47. Amgen. A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less. 〈https://clinicaltrials.gov/ct2/show/NCT01375777〉 (2021).
48. Amgen. Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH. https://clinicaltrials.gov/ct2/show/NCT02392559 (2020).
49. Amgen. Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics. 〈https://clinicaltrials.gov/ct2/show/NCT02189837〉 (2018).
50. Goicoechea, M. Comparative Pilot Study of the Effectiveness of Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT03429998〉 (2018).
51. Havenon, A. de. PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis. https://clinicaltrials.gov/ct2/show/NCT03507374 (2020).
52. Johns Hopkins University. Effect of Evolocumab on Coronary Endothelial Function. 〈https://clinicaltrials.gov/ct2/show/NCT03500302〉 (2020).
53. Johns Hopkins University. Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study. 〈https://clinicaltrials.gov/ct2/show/NCT03515304〉 (2022).
54. LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy - Full Text View - ClinicalTrials.gov. 〈https://clinicaltrials.gov/ct2/show/NCT01380730〉.
55. MD, N.L. Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab - a Pilot Study. 〈https://clinicaltrials.gov/ct2/show/NCT02992301〉 (2019).
56. Minneapolis Heart Institute Foundation. Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial. 〈https://clinicaltrials.gov/ct2/show/NCT03542110〉 (2021).
57. Minno, M.D. Subclinical Atherosclerosis in Patients With Familial Hypercholesterolemia Treated With Evolocumab®. https://clinicaltrials.gov/ct2/show/NCT04313270 (2021).
58. Novartis Pharmaceuticals. An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3). https://clinicaltrials.gov/ct2/show/NCT03060577 (2022).
59. Radboud University Medical Center. Functional Improvement of Non-infarcT relaTed Coronary Artery Stenosis by Extensive LDL-C Reduction With a PCSK9 Antibody. 〈https://clinicaltrials.gov/ct2/show/NCT04141579〉 (2022).
60. Regeneron Pharmaceuticals. A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin. 〈https://clinicaltrials.gov/ct2/show/NCT01730040〉 (2015).
61. Regeneron Pharmaceuticals. A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin. 〈https://clinicaltrials.gov/ct2/show/NCT01730053〉 (2020).
62. Regeneron Pharmaceuticals. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins. 〈https://clinicaltrials.gov/ct2/show/NCT01709513〉 (2020).
63. Regeneron Pharmaceuticals. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT01926782〉 (2017).
64. Regeneron Pharmaceuticals. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT03156621〉 (2021).
65. Regeneron Pharmaceuticals. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT01709500〉 (2015).
66. Sanofi A. Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥100 mg/dL (≥2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT01812707〉 (2016).
67. Sanofi. A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT01644474〉 (2015).
68. Sanofi. A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT02715726〉 (2019).
69. Sanofi. A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT01644188〉 (2016).
70. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Alirocumab in Chinese Healthy Subjects. 〈https://clinicaltrials.gov/ct2/show/NCT02979015〉 (2017).
71. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan. 〈https://clinicaltrials.gov/ct2/show/NCT02289963〉 (2017).
72. Sanofi. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin. 〈https://clinicaltrials.gov/ct2/show/NCT02584504〉 (2019).
73. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT01644175〉 (2015).
74. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C Higher or Equal to 160mg/dL With Their Lipid-Modifying Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT01617655〉 (2016).
75. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy. 〈https://clinicaltrials.gov/ct2/show/NCT01623115〉 (2016).
76. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin. 〈https://clinicaltrials.gov/ct2/show/NCT02023879〉 (2018).
77. Sanofi. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome. https://clinicaltrials.gov/ct2/show/NCT01663402 (2019).
78. Sanofi. A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin. 〈https://clinicaltrials.gov/ct2/show/NCT02984982〉 (2019).
79. Sanofi. A. Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol. https://clinicaltrials.gov/ct2/show/NCT01959971 (2017).
80. Sanofi. An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase. 〈https://clinicaltrials.gov/ct2/show/NCT02890992〉 (2019).
81. Sanofi. Long-term Safety and Tolerability of SAR236553 (REGN727) in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study. 〈https://clinicaltrials.gov/ct2/show/NCT01507831〉 (2015).
82. Sanofi. Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia. 〈https://clinicaltrials.gov/ct2/show/NCT01954394〉 (2018).
83. University Hospital Inselspital, Berne. Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging Study. https://clinicaltrials.gov/ct2/show/NCT03067844 (2022).
84. University Hospital Inselspital, Berne. EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study. 〈https://clinicaltrials.gov/ct2/show/NCT03287609〉 (2019).
85. Washington University School of Medicine. Effect of Alirocumab on Reverse Cholesterol Transport in Humans. https://clinicaltrials.gov/ct2/show/NCT03014830 (2018).
86. Ranade, P. High Cholesterol: PCSK9s. ICER 〈https://icer.org/assessment/high-cholesterol-2015/〉.
87. COVID-19 vaccine development and a potential nanomaterial path forward10.1038/s41565-020-0737-y ↗
88. Moving towards a new class of vaccines for non-infectious chronic diseases10.1586/14760584.2016.1159136 ↗
89. Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system10.1016/j.atherosclerosis.2019.02.001 ↗
90. A single-dose, implant-based, trivalent virus-like particle vaccine against “cholesterol checkpoint” proteins10.1002/adtp.202100014 ↗
91. CD8+ T cells in autoimmunity10.1016/j.coi.2005.09.014 ↗
92. CD8+ T cells mediate the athero-protective effect of immunization with an apob-100 peptide10.1371/journal.pone.0030780 ↗
93. Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis10.1172/jci.insight.149741 ↗
94. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates10.1038/s41586-021-03534-y ↗
95. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis10.1161/01.ATV.21.1.108 ↗
96. Timing affects the efficacy of LDL immunization on atherosclerotic lesions in apo E (−/−) mice10.1016/j.atherosclerosis.2004.04.016 ↗
97. Lesion development and response to immunization reveal a complex role for CD4 in atherosclerosis10.1161/01.RES.0000156889.22364.f1 ↗
98. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis10.1161/CIRCULATIONAHA.106.615609 ↗
99. Effect of immunization against ox-LDL with two different antigens on formation and development of atherosclerosis10.1186/1476-511X-6-32 ↗
100. Vaccination using oxidized low-density lipoprotein-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice10.1093/cvr/cvp338 ↗